Internal Medicine, Nephrology · Mayaguez, PR
NPI
1912022310
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
359 Ave Hostos Ste 201
Mayaguez, PR, 00680
Phone (939) 475-3432
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
182 services
Medicare patients, 2024
53
Average age 74
Drug cost, 2024
$1.6M
4,949 prescriptions
Company payments, 2025
$50K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William O Hurtado-Santiago was code 99232 (hospital e&m - subsequent), 79 times for 20 patients. In total William O Hurtado-Santiago billed 182 services in 13 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-03-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 79 | 20 | $59.96 | $4,736 |
| 99214 Office E&M - Established | Office | 21 | 17 | $89.97 | $1,889 |
| 99213 Office E&M - Established | Office | 16 | 15 | $71.08 | $1,137 |
By year: 2022 $40K for 190 services; 2023 $31K for 188 services; 2024 $24K for 182 services.
Medicare prescription drug claims, 2024
In 2024, the drug William O Hurtado-Santiago prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 880 prescriptions and refills. In total William O Hurtado-Santiago wrote 4,949 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 880 | 1,014 | 182 | $591K |
| Atorvastatin Calcium Generic | 475 | 665 | 128 | $3,766 |
| Jardiance Empagliflozin | 445 | 495 | 100 | $304K |
| Losartan Potassium Generic | 357 | 595 | 101 | $3,738 |
| Amlodipine Besylate Generic | 244 | 295 | 57 | $998 |
| Allopurinol Generic | 223 | 286 | 58 | $1,233 |
| Kerendia Finerenone | 178 | 192 | 35 | $128K |
| Glyxambi Empagliflozin/Linagliptin | 123 | 133 | 23 | $82K |
| Sevelamer Carbonate Generic | 119 | 123 | 36 | $13K |
| Rosuvastatin Calcium Generic | 116 | 152 | 32 | $812 |
| Lisinopril Generic | 107 | 141 | 30 | $483 |
| Irbesartan Generic | 97 | 141 | 27 | $2,170 |
| Metoprolol Succinate Generic | 75 | 119 | 24 | $801 |
| Trijardy Xr Empaglifloz/Linaglip/Metformin | 74 | 78 | 17 | $45K |
| Lokelma Sodium Zirconium Cyclosilicate | 63 | 67 | 21 | $54K |
Brand drugs: - claims; generic drugs: 2,909 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William O Hurtado-Santiago $50K ($50K in general payments such as food, travel and fees) from 20 companies. The largest payer was Calliditas Therapeutics US Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 23 | $19K |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $15K |
| Lilly USA, LLC LLY | 17 | $12K |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $1,785 |
| NxStage Medical, Inc. | 3 | $343 |
| Travere Therapeutics, Inc. TVTX | 2 | $263 |
| Amgen Inc. AMGN | 4 | $188 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $146 |
| Apellis Pharmaceuticals, Inc. APLS | 1 | $125 |
| Shionogi Inc 4507.T | 1 | $123 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.